Last reviewed · How we verify

NCT04252599

Upper Airway Function and Cardiorespiratory Performance in Impair Trunk Motor Control Multiple Sclerosis Patients.

Status unknown Last updated 5 February 2020
What this trial tests

trial in Multiple Sclerosis in 60 participants. Status unknown.

Timeline
20 November 2019
Primary endpoint
2 December 2019
24 January 2020

Quick facts

Lead sponsorUniversidad de Granada
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date20 November 2019
Primary completion2 December 2019
Estimated completion24 January 2020
Sites1 location across Spain

Conditions studied

Sponsor

Universidad de Granada — full company profile →

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple sclerosis is a chronic and highly disabling disorder with considerable social impact and economic consequences. It is caused by damage to the myelin sheath, the protective covering that surrounds nerve cells. Different areas are affected, including upper airway function, trunk motor control and cardiorespiratory performance. The aim of this study was to determinate the relevance of trunk motor control in upper airway function and cardiorespiratory performance in patients with multiple sclerosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Universidad de Granada trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04252599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing